Aim: to investigate the influence of alpha1-antitrypsin (A1-AT) nebulization on levels of
A1-AT in BAL and plasma in patients with stable bronchiectasis.
Method: single-blind placebo-controlled randomised clinical trial. 19 stable bronchiectasis
patients with chronic bronchial infection and 10 control patients (without bronchiectasis)
underwent a bronchoscopy in order to assess levels and inhibitory capacity of A1AT and
neutrophilic elastase. Afterwards, the 19 bronchiectasis patients were randomly allocated to
receive inhaled A1AT 250mg diluted in 10ml 0.9% saline solution once a day for a month (Group
A, n: 10) or placebo (10ml 0.9% saline solution; group B, n: 9). A new BAL was performed in
both groups (A and B) 24 hours after the end of treatment (1month) to re-analyze A1AT and NE.
Phase:
N/A
Details
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute
Collaborators:
Bayer Instituto de Salud Carlos III Sociedad Española de Neumología y Cirugía Torácica